Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA (TRMED) - Net Assets
Latest net assets as of June 2025: Nkr473.50 Million NOK
Based on the latest financial reports, Thor Medical ASA (TRMED) has net assets worth Nkr473.50 Million NOK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr561.00 Million) and total liabilities (Nkr87.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr473.50 Million |
| % of Total Assets | 84.4% |
| Annual Growth Rate | 17.2% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 151.22 |
Thor Medical ASA - Net Assets Trend (2020–2024)
This chart illustrates how Thor Medical ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Thor Medical ASA (2020–2024)
The table below shows the annual net assets of Thor Medical ASA from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr337.10 Million | +23.97% |
| 2023-12-31 | Nkr271.93 Million | +325.93% |
| 2022-12-31 | Nkr63.84 Million | -54.57% |
| 2021-12-31 | Nkr140.52 Million | -21.35% |
| 2020-12-31 | Nkr178.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Thor Medical ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4595400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr56.10 Million | 16.64% |
| Other Components | Nkr344.10 Million | 102.08% |
| Total Equity | Nkr337.10 Million | 100.00% |
Thor Medical ASA Competitors by Market Cap
The table below lists competitors of Thor Medical ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transat A.T. Inc
PINK:TRZBF
|
$48.69 Million |
|
BIOPORTO A/S B DK 1
F:2P4
|
$48.70 Million |
|
EMERALD HLDG INC. DL-01
F:EM7
|
$48.72 Million |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
$48.72 Million |
|
Ilshinstone
KO:007110
|
$48.68 Million |
|
ASG Corp
VN:ASG
|
$48.67 Million |
|
Hwa Sung Ind
KO:002460
|
$48.66 Million |
|
Cinclus Pharma Holding AB (publ)
F:J8P
|
$48.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Thor Medical ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 271,925,000 to 337,100,000, a change of 65,175,000 (24.0%).
- Net loss of 42,208,000 reduced equity.
- Share repurchases of 114,346,000 reduced equity.
- New share issuances of 114,346,000 increased equity.
- Other factors increased equity by 107,383,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-42.21 Million | -12.52% |
| Share Repurchases | Nkr114.35 Million | -33.92% |
| Share Issuances | Nkr114.35 Million | +33.92% |
| Other Changes | Nkr107.38 Million | +31.85% |
| Total Change | Nkr- | 23.97% |
Book Value vs Market Value Analysis
This analysis compares Thor Medical ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.87x to 3.31x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Nkr2.53 | Nkr4.73 | x |
| 2021-12-31 | Nkr1.48 | Nkr4.73 | x |
| 2022-12-31 | Nkr0.55 | Nkr4.73 | x |
| 2023-12-31 | Nkr1.56 | Nkr4.73 | x |
| 2024-12-31 | Nkr1.43 | Nkr4.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Thor Medical ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-12.52%) is above the historical average (-211.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -233.44% | 0.00% | 0.00x | 1.76x | Nkr-434.94 Million |
| 2021 | -314.06% | 0.00% | 0.00x | 2.11x | Nkr-455.35 Million |
| 2022 | -487.52% | 0.00% | 0.00x | 1.72x | Nkr-317.63 Million |
| 2023 | -9.77% | 0.00% | 0.00x | 1.22x | Nkr-53.75 Million |
| 2024 | -12.52% | 0.00% | 0.00x | 1.23x | Nkr-75.92 Million |
Industry Comparison
This section compares Thor Medical ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $58,936,218
- Average return on equity (ROE) among peers: -99.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Thor Medical ASA (TRMED) | Nkr473.50 Million | -233.44% | 0.18x | $48.68 Million |
| Arctic Bioscience AS (ABS) | $287.28 Million | -11.84% | 0.14x | $3.71 Million |
| Aqua Bio Technology ASA (ABTEC) | $8.32 Million | -176.71% | 0.95x | $7.08 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $76.32 Million |
| Circa Group AS (CIRCA) | $41.74 Million | -16.77% | 0.13x | $3.57 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $16.90 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.19 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.31 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $432.13K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.63 Million |